Clinical studies overview Search menu
  1. Home
  2. Clinical studies overview
  3. 222730

M24BHG: 222730

A Phase I clinical study of the safety, tolerability, pharmacokinetics, and clinical activity of GSK5733584 as an injection in subjects with advanced solid tumors.

  • NKI Code: M24BHG
  • Code firm: 222730
  • Code clinicaltrials.gov: NCT06431594
Principal investigator

Dr. M. van Dongen

Medication

GSK5733584, an ADC (anti-B7-H4 IgG1 monoclonal antibody with topoisomerase I inhibitor (HS-9265)).

Summary

In this study, we will look at how safe the investigational drug is GSK5733584 in the treatment of cancer and how well it works. In addition, it is investigated how the body reacts to
GSK5733584 and at different strengths of the agent.

Read more on clinicaltrials.gov.

Notes

  • Dose expansion: ovary – paused
  • Dose expansion: endometrium – open
onload

Disclaimer

This translation was generated automatically based on information in Dutch. It has not been reviewed by a medical specialist. The purpose of this translation is to make our information accessible to non-Dutch speakers. However, this information should not be considered a substitute for medical advice from your treating physician. The Netherlands Cancer Institute cannot guarantee the accuracy of this translation. For medical questions or advice, please consult your physician.

This website uses cookies

The NKI Centre for Early Clinical Studies places functional cookies and analytical cookies with very little or no privacy impact, unless you give permission for other cookies (as shown below). More information can be found in our cookie statement at the bottom of this page.

Functional and analytical
[1]
  • A working website
    By placing this cookie, we can offer you a functional website and we as an organization receive anonymized website statistics.
Media
[1]
  • YouTube
    This allows you to watch the videos on our website

Cookie Information

Accept cookies!